N
GILD icon

Natixis’s Gilead Sciences GILD Stock Holding History

Natixis’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250,000
Closed -$34.8M – 1242
2026
Q1 		$34.8M Buy
+250,000
New +$35M 0.12% 113

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's GILD Position: Q2 2026 in Review

Natixis reduced its Gilead Sciences (GILD) stake by 8.2% in Q2 2026, selling an estimated $1.68M and leaving 143,928 shares worth $18.2M. The position accounts for 0.07% of the portfolio, ranked #185.

Natixis first reported a position in GILD in Q3 2015 and has held it in 43 quarters since. The position peaked at $218M in Q3 2018. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Natixis held 143,928 shares of Gilead Sciences worth $18.2M as of Q2 2026.
  • Natixis sold 12,787 Gilead Sciences shares in Q2 2026, an estimated $1.68M.
  • Gilead Sciences made up 0.07% of Natixis's portfolio in Q2 2026, its #185 holding.
  • Natixis first reported a position in Gilead Sciences in Q3 2015 and has held it in 43 quarters since.
  • Natixis's Gilead Sciences position peaked at $218M in Q3 2018.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.